The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study.

PCOS (Polycystic Ovary Syndrome) occurs due to hyperandrogenism, excessive androgen, abnormal growth, steroidogenesis and seems to be associated with abnormal Vascular endothelial growth factor (VEGF) level in serum. The treatment is provided on the basis of body symptoms to mute the excess production of hormone. The study assessed the effect of prednisolone treatment on the concentration of VEGF, pregnancy outcomes and variants of VEGF SNPs. In the current retrospective study, the samples were collected from PCOS female patients who received prednisolone and those who did not received it, were compared along with control, in terms of pregnancy results and the association complications. The results inferred that the prednisolone made the concentration of VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones. But the reduced normal limits were achieved only among few patients whereas no significant improvement found in the women who received prednisolone and control, in terms of pregnancy outcomes or complications. Further, there were no relations between the impact of treatment and the variants of VEGF SNPs. To conclude, there is no solid evidence found in the current study with regards to notable beneficial effect when the patients were treated with prednisolone, either in pregnancy outcomes or VEGF SNPs. The current study results should be considered only as a preliminary one since the genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc. The results yielded may not be generalized due to differences in genetic background.